%PDF-1.4
%
4 0 obj
<>
endobj
5 0 obj
<>stream
Gong M.; Pan H.; Yang X.; Pan C.; Ning Y.; Li J.
Prolonged Intermittent Renal Replacement Therapy Combined with Hemoperfusion Can Improve Early Recovery of Moderate and Severe Acute Pancreatitis, Especially in Patients with Acute Kidney Injury
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.<br />
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.<br />
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Introduction: The aim of this study was to investigate the efficacy of prolonged intermittent renal replacement therapy (PIRRT) plus hemoperfusion (HP) in treating moderately severe acute pancreatitis (MSAP) and severe acute pancreatitis (SAP). Methods: A total of 105 MSAP and SAP patients were enrolled. Sixty of them received routine internal medical therapy (control group), and 45 received PIRRT and HP in addition to routine internal medical therapy (PIRRT + HP group). The vital signs, laboratory results, and the Acute Physiology and Chronic Health Evaluation II (APACHE II) score were compared between the two groups before treatment and on the 3rd and 7th days of treatment. Results: No deaths or treatment-related serious adverse reactions occurred in both groups. After 3 and 7 days of treatment, the APACHE II score decreased more significantly in the PIRRT + HP group than in the control group (3 days: 5.47 [±3.30] vs. 7.53 [±3.89], p = 0.005. 7 days: 4.82 [±3.49] vs. 6.87 [±3.54], p = 0.004). After 3 days of treatment, the inflammatory combination parameters systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) in the PIRRT + HP group decreased more significantly than those in the control group (SII: 1,239.00 [737.80–1,769.00] vs. 2,013.00 [1,260.00–3,167.00], p = 0.001. NLR: 8.78 [±4.52] vs. 11.88 [±7.30], p = 0.009). After 7 days of treatment, SII, NLR, and hypersensitive C-reactive protein decreased significantly compared with baseline, but no statistical differences between the two groups were observed. AST in both groups remained stable with treatment. There was no significant difference in baseline creatinine between the two groups of AKI patients, but after 3 and 7 days of treatment, the proportion of acute kidney injury (AKI) patients in the PIRRT + HP group whose creatinine decreased by 50% from baseline or fell to the normal range was significantly higher than that in the control group (p < 0.05). Conclusion: PIRRT + HP therapy could not only improve the general conditions, as measured by APACHE II score, but also reduce the inflammatory cascade of patients with acute pancreatitis. For MSAP and SAP patients complicated with AKI, this therapy may accelerate the recovery of renal function.
Acute pancreatitis
Prolonged intermittent renal replacement therapy
Hemoperfusion
APACHE II
Acute kidney injury
endstream
endobj
6 0 obj
<>stream
x+ |
endstream
endobj
7 0 obj
<>stream
xm?0G|ߨCӻ$m+\jQAooODuGBwW֩Ip@<(~{F xQrdb(ČfџӦݷ>kL5V%d\9oFoԥtfmޫܘܐ1`6`G ',
endstream
endobj
8 0 obj
<>stream
x+ |
endstream
endobj
9 0 obj
<>stream
xm
@EwNL_ӥ`enjQFD@1ׁt}twCPnuߞI'\ڼbjFq[l5"8βbNߌHa0y\[rx/STHL5y,r`*,
endstream
endobj
10 0 obj
<>stream
x+ |
endstream
endobj
11 0 obj
<>stream
xm
@E[j>lJ`d[5͢ߛ9F]ѡ+p$p#=#L(92bx1Yzi-SUw ,;W雑)ta?+]mܘܐ1`6`G -,
endstream
endobj
12 0 obj
<>stream
x+ |
endstream
endobj
13 0 obj
<>stream
xm?0G|ߨCӻM+\jQAooODuGS(BKăgx%G&,=sڴgTc]BE85sk
U{2Llş>stream
x+ |
endstream
endobj
15 0 obj
<>stream
xm
1E|-L$Rp%(A-ĿwGDs`uGS(Σ%A3<ċ#[:F)f4K60X~rQTxfdF*]Okf׆
@6XOnU33,
endstream
endobj
16 0 obj
<>stream
x+ |
endstream
endobj
17 0 obj
<>stream
xm
0EEә<ڤKKJn֢hަ |{bBĽ0#-Qx`xJ",1lj&/q״
sM4SLIWRB>stream
x+ |
endstream
endobj
19 0 obj
<>stream
xm
0EEәII>,ܪEu!MA3;AnĂ{f~,
28bHb[F">stream
x+ |
endstream
endobj
21 0 obj
<>stream
xm
0EEә<ڤKKJn֢hަ |{b!{'fa,-G)MZǰ,⳿]6ؿ*%6?DdlL1
&_I!0yRQ9R"TzGx-5
endstream
endobj
22 0 obj
<>stream
x+ |
endstream
endobj
23 0 obj
<>stream
xm
@E[j̾Mla&Efaajqȷ'vwbƲ(x<0< WBZ[2lj&/q״
sM4դ+q鏇KR^**"W*W*ҕXAo-9
endstream
endobj
24 0 obj
<>stream
x+ |
endstream
endobj
25 0 obj
<>stream
xm
0EEә<ڤKKJn֢hަ |{b!{'fa,=G)MZǰ,⳿]6ؿ*%6?DdlL1
&_I!0yRQ9R"TzGx-=
endstream
endobj
26 0 obj
<>stream
x+ |
endstream
endobj
27 0 obj
<>stream
xm
0EEәII>,ܪEu!MA3;An${f~,ᏊQU1$-#d%욶Ua ! ,++)ta>&N{B"`Ta[zU|P-/
endstream
endobj
30 0 obj
<>stream
H|W]sH}GR+@do&Sly]S-h4Ҁ0),8s]ϗm{*a^+=#tg]b7YJ6lm({_۫osxyHB&Sg2dɶ9W,>$lj6YVwukt5v^Bv`&uffw8fV61L{ūڜY!ёtp%CԖJ5f?2/5Npy
[aQ{xx}(d}W55bQ-rwk^'n3?l,nP~>QQ_CI^f7.Sk$'Q*yBxi7ՠ`A4(J #Yun+5-~Ws48/f[Xo[rśFe zCQlV##k hLB+{VB)Z [{OOwކEI%3ǿ0l mʞ\,ޘ<-FjΡ.u6c.R?S(~Ã*;g`uWa}Gs#ЪteKܠ@,U
MAלVT2FGkuat%lGfP1!ɅRTqhhHm j9pt,ތ.XU:X,jq~|`w"gB.>lɆTkYBv;sאe.
|a`7oQ=H-R^yE=GLϔ`Dt-PA" g}e͊H{mlr-AԂp5E!ml
**`vZ359/9`ڜVX lÇ<}}F}vf`Fׅgjt}o/缺H*dhbN#кq>X)~J_tc;]@SMr]UFk